A detailed history of Regentatlantic Capital LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Regentatlantic Capital LLC holds 11,193 shares of MRNA stock, worth $443,130. This represents 0.04% of its overall portfolio holdings.

Number of Shares
11,193
Previous 14,329 21.89%
Holding current value
$443,130
Previous $2.05 Million 35.32%
% of portfolio
0.04%
Previous 0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$118.07 - $194.18 $370,267 - $608,948
-3,136 Reduced 21.89%
11,193 $1.32 Million
Q2 2022

Aug 15, 2022

BUY
$117.13 - $176.59 $8,433 - $12,714
72 Added 0.51%
14,329 $2.05 Million
Q1 2022

May 02, 2022

BUY
$126.46 - $235.05 $482,191 - $896,245
3,813 Added 36.51%
14,257 $2.46 Million
Q4 2021

Jan 27, 2022

SELL
$225.82 - $368.51 $679,266 - $1.11 Million
-3,008 Reduced 22.36%
10,444 $2.65 Million
Q3 2021

Nov 15, 2021

BUY
$221.9 - $484.47 $2.69 Million - $5.88 Million
12,135 Added 921.41%
13,452 $5.18 Million
Q2 2021

Aug 12, 2021

BUY
$129.91 - $234.98 $171,091 - $309,468
1,317 New
1,317 $309,000
Q1 2021

Apr 29, 2021

SELL
$109.18 - $185.98 $540,004 - $919,857
-4,946 Closed
0 $0
Q4 2020

Feb 04, 2021

SELL
$65.74 - $169.86 $100,910 - $260,735
-1,535 Reduced 23.68%
4,946 $517,000
Q3 2020

Oct 13, 2020

SELL
$54.34 - $94.85 $108 - $189
-2 Reduced 0.03%
6,481 $459,000
Q2 2020

Aug 13, 2020

SELL
$29.67 - $80.0 $120,282 - $324,320
-4,054 Reduced 38.47%
6,483 $416,000
Q1 2020

May 14, 2020

SELL
$17.78 - $31.58 $69,270 - $123,035
-3,896 Reduced 26.99%
10,537 $316,000
Q4 2019

Feb 04, 2020

SELL
$13.93 - $21.28 $27,860 - $42,560
-2,000 Reduced 12.17%
14,433 $282,000
Q3 2019

Oct 22, 2019

SELL
$12.26 - $18.07 $36,780 - $54,210
-3,000 Reduced 15.44%
16,433 $262,000
Q2 2019

Jul 23, 2019

BUY
$13.7 - $28.34 $266,232 - $550,731
19,433 New
19,433 $284,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.5B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Regentatlantic Capital LLC Portfolio

Follow Regentatlantic Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Regentatlantic Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Regentatlantic Capital LLC with notifications on news.